Hodgkin's disease

3 trials MedDRA PT
3 Registered trials
0 Recruiting
2 Unique sponsors
1 Unique IMPs
2 Commercial trials
Drug classes (ATC)
— ATC code not specified 2
L Oncology (ATC L) 1
Mechanism of action (INN-stem analysis)
Antibody-drug conjugate (ADC) 1 substance
Phase II: 1 Phase I: 2

Filter these 3 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 3 trials

Phase II

1 trial
  • European Organisation For Research And Treatment Of Cancer Academic
    BRENTUXIMAB VEDOTIN
    2023-508478-27-00 7 countries 2019 n=7
    Ended

Phase I

2 trials
  • Seagen Inc. Commercial
    IMP not specified
    2022-502390-41-00 4 countries 2024 n=35
    Ended
  • Seagen Inc. Commercial
    IMP not specified
    2023-505813-26-00 5 countries 2024 n=48
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Seagen Inc. Commercial 2 Phase I 0
European Organisation For Research And Treatment Of Cancer Academic 1 Phase II 0
New trials by year
2019
1
2024
2
← All indication landscapes